Oregon Public Employees Retirement Fund acquired a new position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 13,134 shares of the specialty pharmaceutical company’s stock, valued at approximately $200,000.
Other hedge funds have also recently bought and sold shares of the company. Quantamental Technologies LLC bought a new position in AMAG Pharmaceuticals during the 4th quarter worth $107,000. First Quadrant L P CA bought a new position in AMAG Pharmaceuticals during the 4th quarter worth $141,000. Birchview Capital LP bought a new position in AMAG Pharmaceuticals during the 4th quarter worth $152,000. Tower Research Capital LLC TRC acquired a new stake in shares of AMAG Pharmaceuticals during the 3rd quarter worth $173,000. Finally, Virtu Financial LLC acquired a new stake in shares of AMAG Pharmaceuticals during the 4th quarter worth $217,000.
Several research firms have recently issued reports on AMAG. Cantor Fitzgerald reissued a “hold” rating and set a $14.00 target price (down from $17.00) on shares of AMAG Pharmaceuticals in a report on Thursday. BidaskClub lowered AMAG Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, March 7th. ValuEngine lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 27th. Zacks Investment Research raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. Finally, B. Riley set a $21.00 target price on AMAG Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, January 16th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $20.21.
AMAG opened at $12.67 on Friday. The firm has a market cap of $439.81 million, a PE ratio of -3.27 and a beta of 0.44. AMAG Pharmaceuticals, Inc. has a 52-week low of $10.70 and a 52-week high of $26.10. The company has a current ratio of 3.17, a quick ratio of 3.01 and a debt-to-equity ratio of 0.35.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, February 7th. The specialty pharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.38. The company had revenue of $88.10 million for the quarter, compared to analyst estimates of $95.21 million. AMAG Pharmaceuticals had a negative return on equity of 17.10% and a negative net margin of 13.07%. AMAG Pharmaceuticals’s quarterly revenue was down 31.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 EPS. Equities analysts forecast that AMAG Pharmaceuticals, Inc. will post -3.05 earnings per share for the current year.
WARNING: “Oregon Public Employees Retirement Fund Acquires Shares of 13,134 AMAG Pharmaceuticals, Inc. (AMAG)” was first reported by Equities Focus and is owned by of Equities Focus. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.equitiesfocus.com/2019/03/17/oregon-public-employees-retirement-fund-acquires-shares-of-13134-amag-pharmaceuticals-inc-amag.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Recommended Story: How is a Moving Average Calculated?
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.